Bevacizumab实验室研究进展

Laboratory research advancement in bevacizumab

血管内皮生长因子（VEGF）是导致眼新生血管性疾病发生、发展的重要因子。Bevacizumab（avastin）是一种人源化全长单克隆IgG抗体，可阻止VEGF—A与其受体在血管内皮表面结合，抑制血管内皮增生和新生血管形成。目前抗VEGF药物被广泛用于眼部新生血管疾病的治疗。由于bevacizumab的安全性较好，成本较低，在世界范围内应用较多。就bevacizumab的通透性、安全性、药代动力学及其离体研究等方面的实验室研究进展进行综述。

Vascular endothelial growth factor （VEGF） is a key factor for neovascular diseases of ophthalmology. Bevacizumab is a full-length,humanized monoclonal IgG antibody,which prevents VEGF-A to combine with its receptors on the endothelial surface, and inhibits the endothelial cell proliferation and new blood vessel formation. Nowadays, anti-VEGF drugs are widely used to treat neovascularization diseases in ophthalmology. Bevacizumab has been more extensively applied because of its high security and low cost. The article reviewed the advancement of laboratory researches on the permeability, safety, pharmacokineties of bevacizumab and research in vitro.